KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation-Reference-Cited by-同舟云学术

KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation

Published:2020-09 Issue:9 Volume:20 Page:602-609
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cowan Andrew J.^ORCID,Green Damian J.^ORCID,Karami Mehdi,Becker Pamela S.,Tuazon Sherilyn^ORCID,Coffey David G.,Hyun Teresa S.,Libby Edward N.,Gopal Ajay K.,Holmberg Leona A.^ORCID

Funder

Millennium-Takeda

Sanofi Genzyme

Seattle Genetics

Celgene

Bio-Line

Bristol-Myers Squibb

Merck Sharpe & Dohme

AbbVie

Glycomimetics

JW Pharmaceuticals

Abbvie, Janssen, Bristol Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference45 articles.

1. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol,2016

2. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies;Sheppard;Biol Blood Marrow Transpl,2012

3. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma;Tuchman;J Clin Apher,2015

4. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy;Cowan;Biol Blood Marrow Transpl,2018

5. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma;Lee;Ann Hematol,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization;Transplantation and Cellular Therapy;2024-08

2. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies;Annals of Hematology;2023-09-05

3. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience;Annals of Hematology;2022-11-16

4. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience;Transplantation and Cellular Therapy;2021-09

5. Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis;Transplantation and Cellular Therapy;2021-08